Mortality rates for Lennox Gastaut syndrome and Dravet syndrome, both developmental epileptic encephalopathies, were ...

Encoded Therapeutics Inc. ("Encoded"), a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders, today announced the appointment of Dr. Joseph Sullivan M.D ...

A sweeping review of more than 2,500 studies reveals that despite booming public enthusiasm, cannabis has strong scientific ...

Additionally, Stoke stock has a 21-day average true range, or ATR, of 7.16%, indicating volatile daily price swings for the ...

Dazzling VW vans decked out in thousands of lights have given a two-year-old boy a festive treat at his home. Fifteen of the ...

Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 ...

Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift ...

EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) ...

For half a century, the University of Utah's Anticonvulsant Drug Development (ADD) Program has been at the forefront of discovery, helping millions of ...

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

A review of 2,500+ studies finds medical cannabis has proven benefits for only a few conditions, while many popular claims ...